Quitting Smoking While on Abilify and Depakine Chrono: Special Considerations
Patients taking Abilify (aripiprazole) and Depakine Chrono (valproate) should use pharmacotherapy such as varenicline or nicotine replacement therapy (NRT) along with behavioral support when quitting smoking, as this combination significantly improves success rates compared to unassisted attempts. 1
Impact of Smoking Cessation on Medication Metabolism
When quitting smoking, several important medication interactions must be considered:
Cytochrome P450 Enzyme Changes: Smoking induces CYP1A2 enzymes through polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke. When you quit smoking, these enzyme levels normalize, which can affect medication metabolism.
Aripiprazole (Abilify): While aripiprazole is primarily metabolized by CYP2D6 and CYP3A4, smoking cessation generally does not significantly affect its metabolism, so dose adjustments are typically not required.
Valproate (Depakine Chrono): Valproate is not significantly affected by smoking status, so dose adjustments are not typically necessary when quitting.
Recommended Smoking Cessation Approach
Step 1: Assess Readiness and Set a Quit Date
- Set a definite quit date within 1-2 weeks of your first consultation 2
- Emphasize complete abstinence as the goal
Step 2: Choose Appropriate Pharmacotherapy
For smokers of 10 or more cigarettes per day, pharmacotherapy is strongly recommended:
- First-line options:
- Varenicline: More than doubles the chances of quitting compared to placebo (for every 10 who quit with placebo, 28 could quit with varenicline) 1
- Nicotine Replacement Therapy (NRT): Combining two types of NRT (patch + gum/lozenge) is as effective as varenicline 1
- Bupropion: Increases cessation rates by 62% compared to placebo 1
Step 3: Implement the "Five As" Strategy 1
- ASK: Systematically inquire about smoking status
- ADVISE: Unequivocally urge quitting
- ASSESS: Determine readiness to quit
- ASSIST: Provide pharmacotherapy and behavioral support
- ARRANGE: Schedule follow-up sessions
Step 4: Follow-up and Monitoring
- Arrange weekly follow-up sessions for at least four weeks 2
- Check abstinence using carbon monoxide measurements in expired air
- Monitor for any psychiatric symptom changes that might affect bipolar disorder management
Special Considerations for Psychiatric Patients
- Psychiatric Stability: Ensure that bipolar disorder is well-controlled before attempting smoking cessation
- Monitoring: Watch closely for any changes in mood or psychiatric symptoms during the quitting process
- Rescue Strategies: If the initial quit attempt fails with varenicline, increasing the dosage enhances abstinence rates. If using NRT and not successful, either increasing the dosage or switching to varenicline can improve outcomes 3
Potential Challenges and Solutions
Challenge 1: Withdrawal Symptoms
- Irritability, anxiety, and mood changes may be difficult to distinguish from bipolar symptoms
- Solution: Use adequate pharmacotherapy doses and consider combination NRT to manage withdrawal symptoms effectively
Challenge 2: Medication Side Effects
- Varenicline may cause nausea, sleep disturbances, and rarely, psychiatric symptoms
- Solution: Start with low doses and titrate up slowly; monitor closely for any mood changes
Challenge 3: Relapse Risk
- High relapse rates are common, especially in psychiatric populations
- Solution: Extended treatment duration may be beneficial; continue follow-up support beyond the initial treatment period
Conclusion
Quitting smoking while on Abilify and Depakine Chrono is both safe and beneficial for long-term health outcomes. Using evidence-based pharmacotherapy combined with behavioral support significantly increases success rates. While smoking cessation doesn't typically require dose adjustments for these specific medications, close monitoring for psychiatric symptom changes is essential.